HTML Microdata document

This HTML5 document contains 41 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n12	http://linked.opendata.cz/resource/drugbank/drug/DB04972/identifier/chemspider/
n9	http://bio2rdf.org/drugbank:
n10	http://linked.opendata.cz/resource/drugbank/drug/DB04972/identifier/pubchem-compound/
adms	http://www.w3.org/ns/adms#
n11	http://linked.opendata.cz/resource/drugbank/drug/DB04972/identifier/pubchem-substance/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n4	http://linked.opendata.cz/resource/drugbank/drug/DB04972/identifier/drugbank/
owl	http://www.w3.org/2002/07/owl#
n5	http://linked.opendata.cz/ontology/drugbank/
n6	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#

Statements

Subject Item: n2:DB04972
rdf:type: n5:Drug
n5:description: Canfosfamide is an active agent in chemotherapy-resistant ovarian cancer.
n5:generalReferences: # Rosen LS, Brown J, Laxa B, Boulos L, Reiswig L, Henner WD, Lum RT, Schow SR, Maack CA, Keck JG, Mascavage JC, Dombroski JA, Gomez RF, Brown GL: Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies. Clin Cancer Res. 2003 May;9(5):1628-38. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12738715 # Rosen LS, Laxa B, Boulos L, Wiggins L, Keck JG, Jameson AJ, Parra R, Patel K, Brown GL: Phase 1 study of TLK286 (Telcyta) administered weekly in advanced malignancies. Clin Cancer Res. 2004 Jun 1;10(11):3689-98. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15173075 # Kavanagh JJ, Gershenson DM, Choi H, Lewis L, Patel K, Brown GL, Garcia A, Spriggs DR: Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer. Int J Gynecol Cancer. 2005 Jul-Aug;15(4):593-600. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16014111 # Manufacturer Site "Link":http://www.telik.com/pipe_telcyta.html
n5:group: investigational
n5:halfLife: 18 min
n5:indication: Intended for the treatment of various forms of cancer.
owl:sameAs: n9:DB04972
dcterms:title: Canfosfamide
adms:identifier: n4:DB04972 n10:6433120 n11:10549844 n12:4938308
n5:mechanismOfAction: S-transferase P1-1 (GST P1-1) is an enzyme overexpressed in many human cancer cells. High levels of GST P1-1 are associated with a poor prognosis and resistance to certain chemotherapeutics. The activation of canfosfamide occurs when GST P1-1 splits canfosfamide into two active fragments: a glutathione analog fragment and an active cytotoxic fragment. The cytotoxic fragment reacts with important cell components, including RNA, DNA and proteins, leading to cell death. The glutathione analog fragment of canfosfamide may remain bound to GST P1-1, which may limit the ability of GST P1-1 to inactivate other cancer drugs.
n5:toxicity: Canfosfamide-related toxicities included grade 1-2 nausea, vomiting, fatigue, transient microscopic hematuria, and anemia.
n5:salt
n5:IUPAC-Name: n6:271B61A9-363D-11E5-9242-09173F13E4C5
n5:InChI: n6:271B61AF-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula: n6:271B61AE-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight: n6:271B61AB-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight: n6:271B61AC-363D-11E5-9242-09173F13E4C5
n5:SMILES: n6:271B61AD-363D-11E5-9242-09173F13E4C5
n5:logP: n6:271B61A8-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count: n6:271B61B5-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count: n6:271B61B6-363D-11E5-9242-09173F13E4C5
n5:InChIKey: n6:271B61B0-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-: n6:271B61B1-363D-11E5-9242-09173F13E4C5
n5:Polarizability: n6:271B61B3-363D-11E5-9242-09173F13E4C5
n5:Refractivity: n6:271B61B2-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count: n6:271B61B4-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism: Humans and other mammals
n5:casRegistryNumber: 439943-59-6
n5:category
n5:Bioavailability: n6:271B61BB-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter: n6:271B61BD-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule: n6:271B61BE-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings: n6:271B61BA-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge: n6:271B61B9-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five: n6:271B61BC-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name: n6:271B61AA-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-: n6:271B61B7-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-: n6:271B61B8-363D-11E5-9242-09173F13E4C5